Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
75 patients around the world
Available in Brazil, United States
Freeline Therapeutics
1Research sites
75Patients around the world
This study is for people with
Gaucher disease
Gaucher disease type 1
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Participants who have previously received FLT201 including those who may have required recommencement or initiation of ERT/substrate reduction therapy.
Participants able to give full informed consent and able to comply with all requirements of the trial.
Sites
Hospital de Clínicas de Porto Alegre - HCPA/UFRGS
Rua Ramiro Barcelos, 2350, Av. Protásio Alves, 211 - Santa Cecília, Porto Alegre - RS, 90035-903
